Dual acting COX/LOX nonsteroidal anti-inflammatory drugs versus traditional COX-2 inhibitors

Abstract

Dual COX/LOX inhibitors, by acting on the two major arachidonic acid metabolic pathways – cyclooxygenase and lipooxygenase, possess a wide range of anti-inflammatory activity. Besides that, dual inhibitors appear to be almost exempt from gastric and cardiovascular toxicity. COX-2 prolonged inhibition by celecoxib led to intensification of lipoperoxidation processes in heart tissue. Activity of enzymes of the antioxidant protection system was increased under the action of celecoxib as well as under the action of thiazolidin-derivatives, possessing dual COX/LOX ingibitory activity. Changes after prolonged dual COX/LOX inhibition were less marked in both tissues, comparing with the action of celecoxib.